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Cardiovascular disease (CVD) is the most common
cause of death after kidney transplantation, accounting
for between 17% and 50% of mortality [1]. In the recent
United States Renal Data System report, the mortality
rate per 100 patient-years from CVD was approximately
0.7 in the first year [2]. This figure slowly increased to
approach 1.0 in the seventh year post-transplantation
[2]. Although this compares favorably with that of
patients on dialysis, it is still much higher than that of
the general population, stratifying for age, gender, and
race [3].
The increased risks could be categorized as follows:
(1) traditional cardiac risk factors (age, sex, diabetes,
hypertension, hyperlipidemia, smoking) — many of
which are present among renal transplant recipients
(RTRs); (2) risk factors related to the post-transplant
state (immunosuppression, graft rejection, viral infec-
tions); and (3) risk factors related to loss of graft
function (anemia, salt and fluid overload, hyperhomo-
cysteinemia) [4]. With these factors in mind, it is
appropriate that RTRs should be considered alongside
patients with chronic renal impairment in the highest
risk group for CVD risk stratification [5].
It is important to note that CVD in RTRs does not
refer to coronary artery disease alone. In RTRs, as in
patients with chronic renal impairment or on dialysis,
left ventricular disorders are commonly caused by
ventricular remodeling in response to hemodynamic
stresses in the presence of anemia and hypertension [6].
Both concentric left ventricular hypertrophy (LVH)
(41%) and eccentric LVH (32%) are common [7].
Regression of LVH occurs after transplantation,
continues beyond the first year, reaches a nadir at
2 years, and persists into the third and fourth post-
transplant years [8]. LVH was a risk factor for death
(RR, 1.9) and congestive heart failure (CHF) (RR,
2.27) [6]. Rigatto et al examined a cohort of RTRs free
of cardiac disease in the first year after transplant, and
found an incidence of de novo CHF of 1.2% per year
[9]. This is much higher than the incidence in the
general population. The major modifiable risk factors
identified were anemia and hypertension [9]. De novo
ischemic heart disease (IHD) occurred simultaneously
with CHF in only one-third of the cases in the study,
suggesting that most CHF developed independently of
coronary artery disease.
The incidence of de novo IHD is 1.2–1.5% per year
[1]. The 10-year cumulative risk of IHD is at least 20%,
or roughly equivalent to that seen in patients with
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previous CVD. Cohort studies in RTRs have confirmed
the importance of Framingham risk factors in the
development of IHD [1,6,10]. After adjusting for
hypertension, donor status, steroid use, cadaveric
donation, renal function, or delayed graft function, acute
rejection has been identified as an independent risk
factor as well [6,10]. It is believed to lead to a state of
chronic inflammation, when atherosclerosis is consi-
dered an inflammatory disorder on its own [11]. It re-
mains controversial as to whether or not asympto-
matic patients with chronic renal impairment or RTRs
warrant screen testing for IHD [12]. Many of these
patients would have some sort of screening prior to
transplantation. Do we need to evaluate RTRs for CVD,
as if they were still on the waitlist? If the answer is
positive, stress imaging studies rather than standard
noninvasive tests would be necessary in view of the
high prevalence of coexisting LVH. Prospective trials
are needed to examine the usefulness of such an
approach and the accuracy of noninvasive imaging.
It is unfortunate that few clinical trials of CVD in
RTRs exist. The optimum management and preven-
tion of CVD in RTRs is, thus, not well defined and can
only be based on extrapolation of data from other
populations.
Approximately 60–75% of RTRs have abnormal
lipids. Increased total and low-density lipoprotein
cholesterol (LDL-C) levels are the most common [5].
Hypercholesterolemia has been shown to be a risk fac-
tor for CVD in RTRs [13,14]. The National Kidney
Foundation’s Kidney Disease Outcomes Quality
Initiative (K/DOQI) in the United States recommends
treatment targets for RTRs as for the highest-risk groups
of the general population [15]. The ALERT trial, a ran-
domized controlled trial of fluvastatin in RTRs with
LDL-C levels between 4 and 9 mmol/L, demonstrated
a significant reduction in nonfatal myocardial infarction
and cardiovascular death [16]. Unlike fluvastatin,
however, most other statins are metabolized through
the same microsomal cytochrome as the calcineurin
inhibitors (CNI). It is recommended that toxicities can
be avoided by starting at half of the usual statin dose,
titrating carefully and monitoring CNI levels. In this
issue of the Hong Kong Journal of Nephrology, Tse et
al addressed this issue by prospectively looking at the
effects of atorvastatin treatment in hypercholesterole-
mic RTRs [17]. Results were compared with historical
controls who had been treated with simvastatin. The
authors found that the use of atorvastatin reduced total
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cholesterol by 31.1%, and LDL-C by 43.4%, after 3
months of treatment. These reductions were sustained
throughout the 3 years of therapy. A significant
reduction in triglycerides was noted after 3 and 9
months, but was not sustained. It is important to note,
as Tse et al have also pointed out, that the therapy was
not associated with any significant effect on cyclospor-
ine trough level and graft function when used long-
term [17]. Randomized controlled trials have also found
no effects of statins on the rate of acute rejection [18].
The prevalence of hypertension in RTRs is 70–85%,
which is greater than in patients with chronic renal
impairment with similar levels of renal function [19].
The pathophysiology is believed to be a combination
of extracellular fluid volume overload caused by
reduced renal function and vasoconstriction aggravated
by immunosuppression, anti-rejection therapy, and the
presence of diseased native kidneys [5]. Since RTRs
are similar to patients with chronic kidney disease, a
target of 130/80 mmHg or lower seems appropriate [20].
The available data on treatment of post-transplant hy-
pertension are insufficient to recommend any class of
antihypertensive agents as preferred agents. However,
by analogy with chronic renal impairment, angiotensin
blockade is probably indicated for RTRs with diabetes,
chronic allograft nephropathy, or CVD [21].
The use of aspirin and beta-blockers following
myocardial infarction in patients with chronic kidney
disease has been associated with improved survival
across a broad spectrum of renal function [22]. Their
use for usual indications is thus warranted in RTRs as
well. Little is known about the role of anemia manage-
ment in the prevention of cardiomyopathy and CHF
in RTRs. The data of Rigatto et al suggests that a
hemoglobin level below 120 g/L may be a causal risk
factor for CHF in RTRs [9]. The association of
hyperglycemia with CVD outcomes in RTRs has not
been studied, nor has the effect of strict glycemic
control. While strict glycemic control in transplant
recipients with diabetes is likely to be beneficial, the
generally accepted target for HbA1c of < 7% may not
be attainable in all patients as a result of the longer
duration of diabetes and the increased insulin resistance
with various immunosuppressive medications [5].
The use of immunosuppressive agents has been
focused on lowering acute rejection rates. Now we
understand that these agents also affect lipid profile,
insulin resistance, blood pressure, and chronic renal
allograft function. The latter, reflecting the impact of
both chronic allograft nephropathy and alloantigen-
independent factors, in turn affects cardiovascular
mortality [23]. Corticosteroid use has been associated
with hyperlipidemia, accelerated atherosclerosis,
altered glucose metabolism, hypertension and
exacerbation of heart failure [24]. The adverse impact
occurs very early after transplantation [25]. Both
steroid-free and early steroid withdrawal protocols have
been tried, with improved CVD risk profiles observed
[26–28]. For the CNIs, tacrolimus has been considered
to have a more favorable overall cardiovascular risk
profile than cyclosporine, with less reported hyper-
lipidemia and hypertension. While there is hot debate
on the difference in CVD risk profile [29] and nephro-
toxicity among the two agents, the negative impact of
CNIs on long-term graft function has long been
appreciated. Thus, CNI minimization, withdrawal, and
even avoidance have been tested, with varying success
[30–33]. Sirolimus has been used in some of these trials,
and hyperlipidemia is a side effect of concern [34].
Mycophenolate mofetil, an immunosuppressive agent
with favorable cardiovascular risk profile, has also been
associated with better preservation of renal function
[23]. This drug, with or without antibody induction,
has been used in many of the steroid or CNI withdrawal
protocols studied. It is tempting to have immuno-
suppressive regimens tailored for individual patients,
considering CVD risk profile, comorbidity and relative
strengths and weaknesses of specific agents [35]. Cau-
tious drug minimalization and conversion strategies
may further help to reduce drug toxicities, preserve
renal function, and avoid cardiovascular injury [35].
RTRs are at high risk for LVH, CHF and IHD. Renal
allograft function is influenced by donor and recipient
variables, as well as post-transplantation events.
Although some of these issues have been successfully
addressed, it is apparent that further improvement in
transplant recipient survival cannot be achieved with-
out paying attention to CVD risk factors. Physicians
looking after RTRs should attend to these cardiovas-
cular risk factors aggressively, making use of the
evidence and strategies mentioned. The usefulness of
therapeutic lifestyle modifications (smoking cessation,
maintenance of ideal body weight, balanced diet, regular
exercise) in this context cannot be overemphasized. The
American Heart Association recommends a moderate
level of physical activity for 30 minutes daily. This level
of activity is manageable in many of our RTRs.
While it is highly credible that interventions of
proven benefit for CVD prevention in the general
population will also benefit RTRs, trials of therapeutic
strategies in RTRs are urgently needed to clarify the
renoprotective and cardioprotective effects of these
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